Ashburton Jersey Ltd Sells 4,809 Shares of Eli Lilly and Company (NYSE:LLY)

Ashburton Jersey Ltd lowered its position in Eli Lilly and Company (NYSE:LLY) by 84.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 917 shares of the company’s stock after selling 4,809 shares during the period. Ashburton Jersey Ltd’s holdings in Eli Lilly and Company were worth $315,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Silicon Valley Capital Partners bought a new stake in Eli Lilly and Company during the first quarter worth $25,000. Bogart Wealth LLC increased its position in Eli Lilly and Company by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after buying an additional 58 shares during the last quarter. Laffer Tengler Investments purchased a new stake in Eli Lilly and Company in the first quarter worth $33,000. Tanglewood Legacy Advisors LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth $37,000. Finally, Freedom Wealth Alliance LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth $37,000. Institutional investors own 81.38% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 27,353 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $454.15, for a total transaction of $12,422,364.95. Following the transaction, the insider now owns 101,446,457 shares in the company, valued at approximately $46,071,908,446.55. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 27,353 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $454.15, for a total transaction of $12,422,364.95. Following the transaction, the insider now owns 101,446,457 shares in the company, valued at approximately $46,071,908,446.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. Insiders have sold a total of 1,036,514 shares of company stock worth $21,107,445,590 in the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.7 %

NYSE LLY opened at $599.54 on Wednesday. Eli Lilly and Company has a 1-year low of $296.32 and a 1-year high of $601.13. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63. The stock has a 50-day moving average of $504.85 and a 200-day moving average of $433.48. The firm has a market cap of $569.14 billion, a PE ratio of 83.39, a price-to-earnings-growth ratio of 2.36 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. During the same quarter in the previous year, the business earned $1.25 EPS. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. As a group, sell-side analysts forecast that Eli Lilly and Company will post 9.83 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio is presently 62.87%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LLY shares. Bank of America raised their target price on Eli Lilly and Company from $500.00 to $600.00 in a research report on Wednesday, August 9th. Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a research report on Tuesday, August 8th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a research report on Wednesday, August 9th. Finally, Argus lifted their price target on Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.